Product Information
MEMANTINE HCL ER 28 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.3422 per EA under NDC 16571085503. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Sep 28, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the memantine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
28 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571085503
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEMANTINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206032FDA Approved
9/28/2016
TE Code
AB
On Market Since
6/1/2025
Pharmacological Classes
Price Statistics
The NADAC for MEMANTINE HCL ER 28 MG CAPSULE has been published 42 times since Dec 17, 2025, and over the history we have for it it has declined 36.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3422 per EA |
|---|---|
| All-time high | $0.5387 (Jan 14, 2026) |
| All-time low | $0.3422 (Sep 23, 2026) |
| 52-week high | $0.5387 |
| 52-week low | $0.3422 |
| Median price | $0.4884 |
| Average price | $0.4627 |
| Largest weekly change | -10.2% (Jun 17, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
memantine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
N-methyl-D-aspartate Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEMANTINE HCL ER 28 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEMANTINE HCL ER 28 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.3422 per EA (NDC 16571085503), effective Sep 30, 2026.
How has the price of MEMANTINE HCL ER 28 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEMANTINE HCL ER 28 MG CAPSULE has declined 36.5%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for MEMANTINE HCL ER 28 MG CAPSULE?
Since Dec 17, 2025, the NADAC for MEMANTINE HCL ER 28 MG CAPSULE has ranged from a low of $0.3422 (Sep 23, 2026) to a high of $0.5387 (Jan 14, 2026), with a median of $0.4884 per EA.
Are there cheaper alternatives to MEMANTINE HCL ER 28 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MEMANTINE HCL ER 28 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures MEMANTINE HCL ER 28 MG CAPSULE?
MEMANTINE HCL ER 28 MG CAPSULE (NDC 16571085503) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.